2 hours ago
1
libre de droit/iStock via Getty Images
Ultragenyx Pharmaceutical (RARE) has announced a transaction involving the sale of an additional 25% of its royalty interest from Kyowa Kirin.
This deal, valued at $400 million, pertains to future sales of Crysvita (burosumab) in the U.S. and Canada, which will now benefit OMERS Life Sciences.
English (US) ·